Design and Statistical Innovations in a Platform Trial for Amyotrophic Lateral Sclerosis
Authors:
Open Access
- 22 June 2023
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 94 (3) , 547-560
Abstract
Platform trials allow efficient evaluation of multiple interventions for a specific disease. The HEALEY ALS Platform Trial is testing multiple investigational products in parallel and sequentially in persons with amyotrophic lateral sclerosis (ALS) with the goal of rapidly identifying novel treatments to slow disease progression. Platform trials have considerable operational and statistical efficiencies compared with typical randomized controlled trials due to their use of shared infrastructure and shared control data. We describe the statistical approaches required to achieve the objectives of a platform trial in the context of ALS. This includes following regulatory guidance for the disease area of interest and accounting for potential differences in outcomes of participants within the shared control (potentially due to differences in time of randomization, mode of administration, and eligibility criteria). Within the HEALEY ALS Platform Trial, the complex statistical objectives are met using a Bayesian shared parameter analysis of function and survival. This analysis serves to provide a common integrated estimate of treatment benefit, overall slowing in disease progression, as measured by function and survival while accounting for potential differences in the shared control group using Bayesian hierarchical modeling. Clinical trial simulation is used to provide a better understanding of this novel analysis method and complex design. ANN NEUROL 2023;94:547–560Keywords
Funding Information
- ALS Association
- Muscular Dystrophy Association
This publication has 35 references indexed in Scilit:
- The Platform TrialJAMA, 2015
- The PRO-ACT databaseNeurology, 2014
- Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trialRevue Neurologique, 2013
- Bayesian hierarchical modeling of patient subpopulations: Efficient designs of Phase II oncology clinical trialsClinical Trials, 2013
- Use of historical control data for assessing treatment effects in clinical trialsPharmaceutical Statistics, 2013
- The Combined Assessment of Function and Survival (CAFS): A new endpoint for ALS clinical trialsAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013
- Philosophy and the practice of Bayesian statisticsBritish Journal of Mathematical and Statistical Psychology, 2012
- I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant ChemotherapyClinical Pharmacology & Therapeutics, 2009
- Bayesian Meta-Analysis of Multiple Treatment Comparisons: An Introduction to Mixed Treatment ComparisonsValue in Health, 2008
- Bayesian approaches to random‐effects meta‐analysis: A comparative studyStatistics in Medicine, 1995